Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Phase 2/3 Completed 136 enrolled Yale University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication.

Timeline

Start: 2017-02-27
Primary completion: 2021-07-23
Completion: 2022-12-16

Outcome

Met primary endpoint

paper Mixed models of complementary measures of binge-eating frequency also indicated that BWL was significantly superior to no BWL. PMID 36285406 ↗

paper Mixed models of percent weight loss both revealed that BWL was significantly superior to no BWL. PMID 36285406 ↗

Publications

Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2022 Dec 1;179(12):927-937. doi: 10.1176/appi.ajp.20220267. Epub 2022 Oct 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	360 mg	Oral
Subject	Naltrexone	Small molecule	32 mg	Oral